Advertisement

Topics

Assessing 18F-Fluorocholine (18F-FCH) PET to Distinguish True Tumor Progression From Pseudoprogression in High-grade Gliomas

2016-08-01 05:12:24 | BioPortfolio

Summary

This is a pilot study. The purpose of this study is to test if an imaging tracer, not approved by the FDA, called 18F-Fluorocholine (18F-FCH) is useful for evaluating this type of cancer. This tracer is used to perform PET scans. The researchers want to see if the 18F-FCH PET scan, using the study tracer 18F-FCH, can improve upon the usual scans at diagnosing or monitoring this type of cancer.

In patients with high-grade gliomas, changes on standard MRI of the brain may reflect true tumor growth or inflammatory changes in response to treatment, called pseudo-progression. It is important to distinguish true tumor growth from inflammation since inflammation indicates the tumor is responding to treatment. With standard MRI, it is difficult to determine if changes following treatment are due to tumor growth or inflammation early on. Researchers hope to learn if the investigational tracer, 18F-FCH, will be able to distinguish true tumor growth from inflammation more accurately than standard MRI or 18F-FDG PET scans.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Conditions

Brain Cancer

Intervention

PET scan, 18F-Fluorocholine (18F-FCH)

Location

Memorial Sloan Kettering Cancer Center
New York
New York
United States
10065

Status

Recruiting

Source

Memorial Sloan Kettering Cancer Center

Results (where available)

View Results

Links

Published on BioPortfolio: 2016-08-01T05:12:24-0400

Clinical Trials [1367 Associated Clinical Trials listed on BioPortfolio]

[18F] Fluorocholine FCH Positron Emission Tomography (PET)/Computed Tomography (CT) for Detection of Prostate Cancer Lymph Nodes Metastases

The objective of this trial is to assess the value of 18F-choline PET/CT for the detection of regional lymph node metastases from prostate cancer. In addition, the investigators want to ev...

18F-fluorocholine PET/CT Imaging in Hyperparathyroidism

To assess the efficiency of 18F-fluorocholine PET/CT in localization of hyperfunctioning parathyroid tissue in hyperparathyroidism, thereby enabling minimally invasive surgical approaches ...

Imaging Brain Tumors With FACBC and Methionine

This research protocol makes pictures of brain tumors. The pictures are made with a positron emission tomography (PET) scanner. PET scans use radioactivity to "see" cancer cells. We are us...

Single Test to ARrive at MS Diagnosis. Using a Single MRI Brain Scan to Help Diagnose Multiple Sclerosis

This is a pilot study (a small scale study testing procedures so that the investigators can apply this to a larger scale study). This study will test the accuracy of a new brain scan (Magn...

Evaluation of Two Radioactive Chemicals to Image mGluR5 Receptors in Brain

Background: - A small brain protein called the metabotropic glutamate receptor subtype 5 (mGluR5) may affect several brain diseases such as autism and depression. Researchers will use 2 ...

PubMed Articles [20511 Associated PubMed Articles listed on BioPortfolio]

Biopsy-Proven Diffuse Mediastinal Prostate Cancer Metastases Negative on 18F-Fluorocholine, Diagnosed on 68Ga-PSMA and 18F-PSMA PET/CT.

A 72-year-old man with prostate cancer (stage T3b, Gleason score 7) treated by radical prostatectomy was found to have biochemical failure (prostate-specific antigen 8.5 ng/mL) and a suspicious growin...

18F-Fluorocholine PET/CT Complementing the Role of Dynamic Contrast-Enhanced MRI for Providing Comprehensive Diagnostic Workup in Prostate Cancer Patients With Suspected Relapse Following Radical Prostatectomy.

The aim of this study was to compare the diagnostic performance of F-fluorocholine (FCH) PET/CT and dynamic contrast-enhanced MRI (DCE-MRI) of pelvis in restaging prostate cancer (PC) patients with bi...

Spectrum Of Brain Abnormalities Detected On Whole Body F-18 FDG PET/CT Scan.

Positron emission tomography (PET) with integrated computed tomography (CT) is a unique modality to noninvasively scan the whole body for diagnosing, staging and assessing response to therapy in vario...

18F-Fluorocholine, 18F-FDG, and 18F-Fluoroethyl Tyrosine PET/CT in Parathyroid Cancer.

We report on a 71-year-old woman presenting with biochemical features indicating recurrent disease in long-term follow-up of left-sided parathyroid carcinoma. She had undergone several surgical proced...

Planar Bone Scan Versus Computerized Tomography in Staging Locally Advanced Breast Cancer in Asymptomatic Patients: Does Bone Scan Change Patient Management Over Computerized Tomography?

The Royal College of Radiologists guidelines from 2013 recommend that contrast-enhanced computerized tomography of chest, abdomen and pelvis (CT TAP) for breast cancer patients with suspected metastas...

Medical and Biotech [MESH] Definitions

The use of combination of imaging techniques or platforms (e.g., MRI SCAN and PET SCAN) encompassing aspects of anatomical, functional, or molecular imaging methods.

A method of differentiating individuals based on the analysis of qualitative or quantitative biological traits or patterns. This process which has applications in forensics and identity theft prevention includes DNA profiles or DNA fingerprints, hand fingerprints, automated facial recognition, iris scan, hand geometry, retinal scan, vascular patterns, automated voice pattern recognition, and ultrasound of fingers.

A cancer registry mandated under the National Cancer Act of 1971 to operate and maintain a population-based cancer reporting system, reporting periodically estimates of cancer incidence and mortality in the United States. The Surveillance, Epidemiology, and End Results (SEER) Program is a continuing project of the National Cancer Institute of the National Institutes of Health. Among its goals, in addition to assembling and reporting cancer statistics, are the monitoring of annual cancer incident trends and the promoting of studies designed to identify factors amenable to cancer control interventions. (From National Cancer Institute, NIH Publication No. 91-3074, October 1990)

A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.

Tissue NECROSIS in any area of the brain, including the CEREBRAL HEMISPHERES, the CEREBELLUM, and the BRAIN STEM. Brain infarction is the result of a cascade of events initiated by inadequate blood flow through the brain that is followed by HYPOXIA and HYPOGLYCEMIA in brain tissue. Damage may be temporary, permanent, selective or pan-necrosis.

More From BioPortfolio on "Assessing 18F-Fluorocholine (18F-FCH) PET to Distinguish True Tumor Progression From Pseudoprogression in High-grade Gliomas"

Quick Search
Advertisement
 

Searches Linking to this Trial